NCT06825078 Performance of Lung MRI Combined to Synthetic CT in the Follow-up of Lung Nodules
| NCT ID | NCT06825078 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Bordeaux |
| Condition | Lung Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 50 participants |
| Start Date | 2025-02-12 |
| Primary Completion | 2029-02 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 50 participants in total. It began in 2025-02-12 with a primary completion date of 2029-02.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Lung cancer screening trials using low-dose chest CT scans have shown a significant reduction of cancer related mortality in subjects at high risk of lung cancer. However, high rate of false positives and overdiagnosis have led to invasive methods, which are not without risks. Evaluation of lung nodules using lung MRI with ultra short echo time sequences (UTE) has been found comparable to chest CT scans. Moreover, MRI has the advantage of multiparametric characterization of lesions using different tissue contrasts. Following the recommendation of the French National Authority for Health (HAS) to evaluate new methods of lung cancer screening, this prospective single center pilot study is designed to evaluate the performance of multiparametric lung MRI combined to synthetic CT in the diagnosis of lung cancer in heavily smokers or ex-smokers professionally exposed to carcinogens
Eligibility Criteria
Inclusion Criteria: * Subject aged between 55 and 74 years * High risk of developing lung cancer: by a combination of exposure to lung carcinogens and smoking (exposure to tobacco at the rate of 30 packs/year or cessation \< 15 years) * Presence of at least one lung solid nodule ≥ 5mm on the initial scan. * Subject able and willing to complete all scheduled visits and assessments. * Subject with health insurance. * Signed informed consent. Exclusion Criteria: * Subject with signs of lung cancer * Subject with history of lung cancer * Presence of severe life-threatening comorbidities at 6 months (recent CVA, recent discovery of advanced stage cancer) * Subject who had already undergone a chest scan less than a year previously * No exposure to occupational lung carcinogens according to the predefined criteria. * No exposure to tobacco or insufficient exposure to tobacco or cessation \> 15 years. * Contra-indication to MRI (Pace maker, implants, claustrophobia…) * Pregnant or breastfeeding woman * Poor understanding of French * Subject under legal protection
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06825078 clinical trial?
This trial is open to participants of all sexes, aged 55 Years or older, up to 74 Years, studying Lung Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06825078 currently recruiting?
Yes, NCT06825078 is actively recruiting participants. Contact the research team at ilyes.ben-lala@chu-bordeaux.fr for enrollment information.
Where is the NCT06825078 trial being conducted?
This trial is being conducted at Pessac, France.
Who is sponsoring the NCT06825078 clinical trial?
NCT06825078 is sponsored by University Hospital, Bordeaux. The trial plans to enroll 50 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.